Latest news with #JanssenResearch&Development
Globe and Mail
07-04-2025
- Health
- Globe and Mail
Ulcerative Colitis Clinical Trials and Studies 2025: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies
DelveInsight's, 'Ulcerative Colitis Pipeline Insight 2025' report provides comprehensive insights about 70+ companies and 75+ pipeline drugs in Ulcerative Colitis Pipeline Landscape. It covers the Ulcerative Colitis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Ulcerative Colitis therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Explore the comprehensive insights by DelveInsight and stay ahead in understanding the Ulcerative Colitis Treatment Landscape. Click here to read more @ Ulcerative Colitis Pipeline Outlook Key Takeaways from the Ulcerative Colitis Pipeline Report In April 2025, Merck Sharp & Dohme LLC announced a study 1's primary hypotheses are that at least 1 tulisokibart dose level is superior to Placebo in the proportion of participants achieving clinical remission according to the Modified Mayo Score at Week 12, and that at least 1 tulisokibart dose level is superior to Placebo in the proportion of participants achieving clinical remission according to the Modified Mayo Score at week 52. Study 2's primary hypothesis is that at least 1 tulisokibart dose level is superior to Placebo in the proportion of participants achieving clinical remission according to the Modified Mayo Score at Week 12. In April 2025, Janssen Research & Development, LLC announced a study is to evaluate the efficacy, including clinical remission of guselkumab subcutaneous (SC) induction compared to placebo in participants with moderately to severely active ulcerative colitis (UC). DelveInsight's Ulcerative Colitis pipeline report depicts a robust space with 70+ active players working to develop 75+ pipeline therapies for Ulcerative Colitis treatment. The leading Ulcerative Colitis Companies such as Oppilan Pharma, Genentech, Teva Branded Pharmaceutical, Boehringer Ingelheim, Sorriso Pharmaceuticals, Reistone Biopharma, Celgene, AnaptysBio, Rise Therapeutics, Merck, AltruBio, AbbVie, Immunic AG, Kissei Pharmaceutical Co, Lmito Therapeutics, Morphic Therapeutic, Oncostellae, Palatin Technologies, and others. Promising Ulcerative Colitis therapies such as VE202, Vancomycin Oral Capsule, PL8177, Mirikizumab, Etrasimod, Efavaleukin alfa, ABBV-668, and others. Discover groundbreaking developments in Ulcerative Colitis therapies! Gain in-depth knowledge of key Ulcerative Colitis clinical trials, emerging drugs, and market opportunities @ Ulcerative Colitis Clinical Trials Assessment Ulcerative Colitis Emerging Drugs Profile Obefazimod: Abivax Obefazimod is an oral small-molecule drug candidate in clinical development for the treatment of moderately to severely active ulcerative colitis (UC) and has demonstrated anti-inflammatory activity in preclinical studies and in both Phase IIa and Phase IIb clinical trials. Currently, the drug is in Phase III stage of its clinical trial for the treatment of ulcerative colitis. ABBV-668: AbbVie ABBV-668 is under development for the treatment of crohn's disease, unspecified immunological disorders and ulcerative colitis. The drug candidate acts by targeting receptor interacting serine/threonine protein kinase 1 (RIPK1). It is administered through oral route. Currently, the drug is in Phase II stage of its clinical trial for the treatment of ulcerative colitis. TEV-48574: Teva Pharmaceutical Anti-TL1A (TEV-'574) is a potentially best-in-class human IgG1 monoclonal antibody that targets tumor necrosis factor (TNF)-like ligand 1A (TL1A), also known as TNF superfamily member 15. TL1A signaling is believed to amplify inflammation and drives fibrosis associated with asthma and inflammatory bowel disease (IBD); thus, targeting TL1A with TEV-'574 may mitigate the over-active immune response in these conditions. Anti-TL1A (TEV-'574) is currently in Phase 2b clinical trials for the treatment of ulcerative colitis (UD) and Crohn's disease (CD), two types of inflammatory bowel disease. The safety and efficacy of anti-TL1A (TEV-'574) have not been reviewed by any regulatory authority. Currently, the drug is in Phase II stage of its clinical trial for the treatment of ulcerative colitis. SOR102: Sorriso Pharmaceuticals SOR102 combines anti-TNF and anti-IL-23 vorabodies into a single dual-acting molecule a trypsin cleavable linker releases the monomers to independently engage their targets throughout intestinal tissue. SOR102 provides combination therapy locally within inflamed tissue with minimal risk of systemic immunosuppression. Overall benefits of dual targeting approach increased efficacy through blockade of different inflammatory mechanisms of IBD. Currently, the drug is in Phase I stage of its clinical trial for the treatment of ulcerative colitis. The Ulcerative Colitis Pipeline Report Provides Insights into The report provides detailed insights about companies that are developing therapies for the treatment of Ulcerative Colitis with aggregate therapies developed by each company for the same. It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Ulcerative Colitis Treatment. Ulcerative Colitis Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects. Ulcerative Colitis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Ulcerative Colitis market Stay informed about the Ulcerative Colitis pipeline trends! Uncover critical updates on therapeutic innovations and their potential impact on patients and the healthcare industry @ Ulcerative Colitis Unmet Needs Ulcerative Colitis Companies Oppilan Pharma, Genentech, Teva Branded Pharmaceutical, Boehringer Ingelheim, Sorriso Pharmaceuticals, Reistone Biopharma, Celgene, AnaptysBio, Rise Therapeutics, Merck, AltruBio, AbbVie, Immunic AG, Kissei Pharmaceutical Co, Lmito Therapeutics, Morphic Therapeutic, Oncostellae, Palatin Technologies, and others. Ulcerative Colitis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Intra-articular Intraocular Intrathecal Intravenous Oral Parenteral Subcutaneous Topical Transdermal Ulcerative Colitis Products have been categorized under various Molecule types such as Oligonucleotide Peptide Small molecule Transform your understanding of the Ulcerative Colitis Pipeline! See the latest progress in drug development and clinical research @ Ulcerative Colitis Market Drivers and Barriers, and Future Perspectives Scope of the Ulcerative Colitis Pipeline Report Coverage- Global Ulcerative Colitis Companies- Oppilan Pharma, Genentech, Teva Branded Pharmaceutical, Boehringer Ingelheim, Sorriso Pharmaceuticals, Reistone Biopharma, Celgene, AnaptysBio, Rise Therapeutics, Merck, AltruBio, AbbVie, Immunic AG, Kissei Pharmaceutical Co, Lmito Therapeutics, Morphic Therapeutic, Oncostellae, Palatin Technologies, and others. Ulcerative Colitis therapies- VE202, Vancomycin Oral Capsule, PL8177, Mirikizumab, Etrasimod, Efavaleukin alfa, ABBV-668, and others. Ulcerative Colitis Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination Ulcerative Colitis Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III "Stay Ahead in Gastroenterology Research–Access the Full Ulcerative Colitis Pipeline Analysis Today! @ Ulcerative Colitis Drugs and Companies Table of Content Introduction Executive Summary Ulcerative Colitis: Overview Pipeline Therapeutics Therapeutic Assessment Ulcerative Colitis– DelveInsight's Analytical Perspective In-depth Commercial Assessment Ulcerative Colitis Collaboration Deals Late Stage Products (Preregistration) Mirikizumab: Eli Lilly and Company Drug profiles in the detailed report….. Late Stage Products (Phase III) Obefazimod: Abivax Drug profiles in the detailed report….. Mid Stage Products (Phase II) ABBV-668: AbbVie Drug profiles in the detailed report….. Early Stage Products (Phase I) SOR102: Sorriso Pharmaceuticals Drug profiles in the detailed report….. Preclinical Stage Products Drug Name: Company Name Drug profiles in the detailed report….. Inactive Products Ulcerative Colitis Key Companies Ulcerative Colitis Key Products Ulcerative Colitis- Unmet Needs Ulcerative Colitis- Market Drivers and Barriers Ulcerative Colitis- Future Perspectives and Conclusion Ulcerative Colitis Analyst Views Ulcerative Colitis Key Companies Appendix About Us DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve. Media Contact Company Name: DelveInsight Business Research LLP Contact Person: Yash Bhardwaj Email: Send Email Phone: 09650213330 Address: 304 S. Jones Blvd #2432 City: Las Vegas State: NV Country: United States Website:
Globe and Mail
12-03-2025
- Health
- Globe and Mail
Burn Pain Market to Reach New Heights in Growth by 2034, DelveInsight Predicts
The Key Burn Pain Companies in the market include - Medical Developments International, Cumberland Pharmaceuticals, Janssen Research & Development, Cephalon, and others. DelveInsight's 'Burn Pain Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Burn Pain, historical and forecasted epidemiology as well as the Burn Pain market trends in the United States, EU4 (Germany, Spain, Italy, France, and United Kingdom) and Japan. Some of the key facts of the Burn Pain Market Report: The Burn Pain market size is anticipated to grow with a significant CAGR during the study period (2020-2034) In August 2024, MediWound Ltd. (Nasdaq: MDWD), a global leader in enzymatic therapeutics for tissue repair, announced that the U.S. Food and Drug Administration (FDA) has approved NexoBrid® (anacaulase-bcdb) for eschar removal in pediatric patients from newborns to 18 years old with deep partial- and full-thickness thermal burns. This approval expands NexoBrid's authorization for all age groups in the U.S., aligning with its approvals in the European Union and Japan. In 2023, the US maintained the largest market share among the 7MM, reaching USD 140 million. Projections indicate that this trend will persist, with the US expected to further strengthen its market dominance and remain the leading player by 2034. In 2023, Germany and the UK in the EU4 and the UK both achieved market shares exceeding USD 20 million, with France following closely behind. In contrast, Italy had the smallest market share among these regions during the same period. Opioid analgesics dominated the current treatment market for both inpatient and outpatient care, with an estimated market value of approximately USD 130 million in 2023. In 2023, the US recorded over 2 million incident cases of burns, with numbers expected to rise by 2034. In 2023, approximately 0.4 million treated incident burn cases requiring pain management therapies were reported in the US, with expectations for change during the study period from 2020 to 2034. The gender distribution indicates a male dominance across the 7MM, with around 0.29 million male cases and 0.26 million female cases reported in the US in 2023. Key Burn Pain Companies: Medical Developments International, Cumberland Pharmaceuticals, Janssen Research & Development, Cephalon, and others Key Burn Pain Therapies: Methoxyflurane (PENTHROX), Caldolor, JNJ-42160443, ACTIQ, and others The Burn Pain epidemiology based on etiology-specific cases analyzed that Etiology Specific Incident Cases of Burns is classified into Flame, Contact, Scald, Electrical, Chemical, and Others The Burn Pain market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Burn Pain pipeline products will significantly revolutionize the Burn Pain market dynamics. Burn Pain Overview An organic tissue injury known as a burn is mostly brought on by heat, radiation, radioactivity, electricity, friction, or chemical contact. Get a Free sample for the Burn Pain Market Report - Burn Pain Epidemiology The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends. Burn Pain Epidemiology Segmentation: The Burn Pain market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into: Total Prevalence of Burn Pain Prevalent Cases of Burn Pain by severity Gender-specific Prevalence of Burn Pain Diagnosed Cases of Episodic and Chronic Burn Pain Download the report to understand which factors are driving Burn Pain epidemiology trends @ Burn Pain Epidemiology Forecast Burn Pain Drugs Uptake and Pipeline Development Activities The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Burn Pain market or expected to get launched during the study period. The analysis covers Burn Pain market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share. The report also covers the Burn Pain Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies. Burn Pain Therapies and Key Companies Burn Pain Market Strengths The increasing incidence of patients with burns is expected to propel the treatment market in the future, adding opportunities for new pharma players Burn Pain Market Opportunities The rising incidence of burn pain indicates increasing pharmacological treatment demands, thereby crafting lucrative opportunities for new pharma players Scope of the Burn Pain Market Report Study Period: 2020–2034 Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan] Key Burn Pain Companies: Medical Developments International, Cumberland Pharmaceuticals, Janssen Research & Development, Cephalon, and others Key Burn Pain Therapies: Methoxyflurane (PENTHROX), Caldolor, JNJ-42160443, ACTIQ, and others Burn Pain Therapeutic Assessment: Burn Pain current marketed and Burn Pain emerging therapies Burn Pain Market Dynamics: Burn Pain market drivers and Burn Pain market barriers Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies Burn Pain Unmet Needs, KOL's views, Analyst's views, Burn Pain Market Access and Reimbursement Table of Contents 1. Burn Pain Market Report Introduction 2. Executive Summary for Burn Pain 3. SWOT analysis of Burn Pain 4. Burn Pain Patient Share (%) Overview at a Glance 5. Burn Pain Market Overview at a Glance 6. Burn Pain Disease Background and Overview 7. Burn Pain Epidemiology and Patient Population 8. Country-Specific Patient Population of Burn Pain 9. Burn Pain Current Treatment and Medical Practices 10. Burn Pain Unmet Needs 11. Burn Pain Emerging Therapies 12. Burn Pain Market Outlook 13. Country-Wise Burn Pain Market Analysis (2020–2034) 14. Burn Pain Market Access and Reimbursement of Therapies 15. Burn Pain Market Drivers 16. Burn Pain Market Barriers 17. Burn Pain Appendix 18. Burn Pain Report Methodology 19. DelveInsight Capabilities 20. Disclaimer 21. About DelveInsight About DelveInsight DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach. Media Contact Company Name: DelveInsight Contact Person: Gaurav Bora Email: Send Email Phone: +14699457679 Address: 304 S. Jones Blvd #2432 City: Las Vegas State: NV Country: United States Website:
Globe and Mail
07-03-2025
- Business
- Globe and Mail
Acute Myeloid Leukemia Clinical Trials and Studies: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies
DelveInsight's, 'Acute Myeloid Leukemia Pipeline Insight' report provides comprehensive insights about 110+ companies and 120+ pipeline drugs in Acute Myeloid Leukemia pipeline landscape. It covers the Acute Myeloid Leukemia pipeline drug profiles, including Acute Myeloid Leukemia clinical trials and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Explore the comprehensive insights by DelveInsight and stay ahead in understanding the Acute Myeloid Leukemia Treatment Landscape. Click here to read more @ Acute Myeloid Leukemia Pipeline Outlook Key Takeaways from the Acute Myeloid Leukemia Pipeline Report In March 2025, Janssen Research & Development, LLC conducted a study to determine the recommended Phase 2 dose(s) (RP2D[s]) of bleximenib in Phase 1 (Part 1 - Dose Escalation) and assess its safety and tolerability at RP2D in Phase 1 (Part 2 - Dose Expansion). The Phase 2 part of the study aims to evaluate the efficacy of bleximenib at the RP2D. In March 2025, Akeso initiated an open-label, Phase Ib/II study involving patients diagnosed with acute myeloid leukemia (AML) with an Eastern Cooperative Oncology Group (ECOG) performance status of 0-3. The study's objective is to evaluate the safety and efficacy of AK117 + azacitidine in AML patients. DelveInsight's Acute Myeloid Leukemia Pipeline analysis depicts a robust space with 110+ active players working to develop 120+ pipeline treatment therapies. The leading Acute Myeloid Leukemia Companies such as GlycoMimetics, BioSight, Merck Sharp & Dohme LLC, Kura Oncology, Senti Biosciences, Chimerix, Takeda, Apollo Therapeutics, Immune-Onc Therapeutics, AbbVie/Genentech, Altor BioScience Corporation, Merck & Co, Astex Pharmaceuticals, Karyopharm Therapeutics, Mesoblast, SELLAS Life Sciences Group, Molecular Partners, Kling Biotherapeutics, HitGen, Chordia Therapeutics, Inc, Cullinan Therapeutics Inc., Aptose Biosciences Inc., Celgene and others. Promising Acute Myeloid Leukemia Therapies such as OCV-501, SEL24/MEN1703, Venetoclax, Alvocidib, TL-895, KRT-232, XY0206, Azacitidine, Venetoclax, and others. Discover groundbreaking developments in Acute Myeloid Leukemia therapies! Gain in-depth knowledge of key Acute Myeloid Leukemia clinical trials, emerging drugs, and market opportunities @ Acute Myeloid Leukemia Clinical Trials Assessment Acute Myeloid Leukaemia Emerging Drugs Profile Uproleselan: GlycoMimetics GlycoMimetics is developing uproleselan, a specific E-selectin antagonist, to be used in combination with chemotherapy to treat patients with Acute Myeloid Leukemia (AML) (AML) and potentially other hematologic cancers. Uproleselan is designed to bind to E-selectin and block the normal processes controlled by E-selectin. E-selectin is expressed on the surface of blood vessels, and its binding to myeloid cells confers a pro-survival effect via NF-kB signaling. Uproleselan is designed to provide a novel approach to disrupting established mechanisms of leukemic cell resistance. It is believed that by binding to E-selectin, uproleselan pushes AML cells out of their protective niche, blocks cellular communication signals that promote survival, and sensitizes cancer cells to the toxic effects of chemotherapy. Currently, the drug is in Phase III stage of its development for the treatment of Acute Myeloid Leukemia (AML). BST-236: BioSight Aspacytarabine (BST-236) is a novel proprietary anti-metabolite. It is composed of cytarabine covalently bound to asparagine, acting as a pro-drug of cytarabine, enabling delivery of high cytarabine doses to leukemia patients with lower systemic exposure to the free drug. Currently, the drug is in Phase II stage of its development for the treatment of Acute Myeloid Leukemia (AML). MK-0482: Merck Sharp & Dohme LLC MK-0482, a novel humanized IgG4 mAb targeting ILT3, is undergoing phase I evaluation ±pembrolizumab (pembro) in advanced solid tumors. MK-0482 ± pembro was generally well tolerated, and combination therapy provided modest antitumor activity in patients with heavily pretreated advanced solid tumors. The RP2D of MK-0482 + pembro is under further evaluation in tumor-specific cohorts. Currently, the drug is in Phase I stage of its development for the treatment of AML. Ziftomenib - Kura Oncology Ziftomenib is a novel, once-daily, oral investigational drug candidate targeting the menin-KMT2A/MLL protein-protein interaction for treatment of genetically defined AML patients with high unmet need. In preclinical models, ziftomenib inhibits the KMT2A/MLL protein complex and exhibits downstream effects on HOXA9/MEIS1 expression and potent anti-leukemic activity in genetically defined preclinical models of AML. Ziftomenib has received Orphan Drug Designation from the U.S. Food and Drug Administration for the treatment of AML. Currently, the drug is in Phase I/II stage of its development for the treatment of AML. SENTI 202: Senti Biosciences SENTI-202 is a first in class Logic-gated CAR-NK product engineered with an OR and a NOT Logic Gate gene circuit approach to enhance therapeutic efficacy and safety, with additional arming via expression of calibrated release IL-15 (crIL-15). A dual targeting activating CAR (aCAR) that recognizes both CD33 and FLT3 tumor antigens improves the anti-tumor activity, ensuring the targeting of AML blasts and LSCs. Currently, the drug is in Preclinical stage of its development for the treatment of AML. The Acute Myeloid Leukemia pipeline report provides insights into The report provides detailed insights about companies that are developing therapies for the treatment of Acute Myeloid Leukemia with aggregate therapies developed by each company for the same. It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Acute Myeloid Leukemia Treatment. Acute Myeloid Leukemia Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects. Acute Myeloid Leukemia Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Acute Myeloid Leukemia market Stay informed about the Acute Myeloid Leukemia pipeline trends! Uncover critical updates on therapeutic innovations and their potential impact on patients and the healthcare industry @ Acute Myeloid Leukemia Unmet Needs Acute Myeloid Leukemia Companies GlycoMimetics, BioSight, Merck Sharp & Dohme LLC, Kura Oncology, Senti Biosciences, Chimerix, Takeda, Apollo Therapeutics, Immune-Onc Therapeutics, AbbVie/Genentech, Altor BioScience Corporation, Merck & Co, Astex Pharmaceuticals, Karyopharm Therapeutics, Mesoblast, SELLAS Life Sciences Group, Molecular Partners, Kling Biotherapeutics, HitGen, Chordia Therapeutics, Inc, Cullinan Therapeutics Inc., Aptose Biosciences Inc., Celgene and others. The Acute Myeloid Leukaemia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as Oral Intravenous Subcutaneous Parenteral Topical Acute Myeloid Leukaemia Products have been categorized under various Molecule types such as Recombinant fusion proteins Small molecule Monoclonal antibody Peptide Polymer Gene therapy Transform your understanding of the Acute Myeloid Leukemia Pipeline! See the latest progress in drug development and clinical research @ Acute Myeloid Leukemia Market Drivers and Barriers, and Future Perspectives Scope of the Acute Myeloid Leukemia Pipeline Report Coverage- Global Acute Myeloid Leukemia Companies- GlycoMimetics, BioSight, Merck Sharp & Dohme LLC, Kura Oncology, Senti Biosciences, Chimerix, Takeda, Apollo Therapeutics, Immune-Onc Therapeutics, AbbVie/Genentech, Altor BioScience Corporation, Merck & Co, Astex Pharmaceuticals, Karyopharm Therapeutics, Mesoblast, SELLAS Life Sciences Group, Molecular Partners, Kling Biotherapeutics, HitGen, Chordia Therapeutics, Inc, Cullinan Therapeutics Inc., Aptose Biosciences Inc., Celgene and others. Acute Myeloid Leukemia Therapies- OCV-501, SEL24/MEN1703, Venetoclax, Alvocidib, TL-895, KRT-232, XY0206, Azacitidine, Venetoclax, and others. Acute Myeloid Leukemia Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination Acute Myeloid Leukemia Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III Stay Ahead in Oncology Research–Access the Full Acute Myeloid Leukemia Pipeline Analysis Today! @ Acute Myeloid Leukemia Drugs and Companies Table of Content Introduction Executive Summary Acute myeloid leukaemia: Overview Pipeline Therapeutics Therapeutic Assessment Acute myeloid leukaemia – DelveInsight's Analytical Perspective Late Stage Products (Phase III) Uproleselan: GlycoMimetics Drug profiles in the detailed report….. Mid Stage Products (Phase II) BST-236: BioSight Drug profiles in the detailed report….. Early Stage Products (Phase I) MK-0482: Merck Sharp & Dohme LLC Drug profiles in the detailed report….. Preclinical and Discovery Stage Products SENTI 202: Senti Biosciences Drug profiles in the detailed report….. Inactive Products Acute myeloid leukaemia Key Companies Acute myeloid leukaemia Key Products Acute myeloid leukaemia- Unmet Needs Acute myeloid leukaemia- Market Drivers and Barriers Acute myeloid leukaemia- Future Perspectives and Conclusion Acute myeloid leukaemia Analyst Views Acute myeloid leukaemia Key Companies Appendix About Us DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve. Media Contact Company Name: DelveInsight Business Research LLP Contact Person: Yash Bhardwaj Email: Send Email Address: 304 S. Jones Blvd #2432 City: Las Vegas State: NV Country: United States Website:
Globe and Mail
19-02-2025
- Health
- Globe and Mail
Crohn's Disease Market Analysis 2034: Clinical Trials, EMA, PDMA, FDA Approvals, Prevalence, NDA Approvals, Medication, Pipeline, Epidemiology and Companies by DelveInsight
Crohn's Disease companies working in the treatment market are Takeda Pharmaceutical, Janssen Pharmaceuticals, UCB, Biogen, AbbVie, AstraZeneca, Tillotts Pharma (a subsidiary of Zeria Pharmaceutical), Gilead Sciences and Galapagos NV, Boehringer Ingelheim, Celgene (part of Bristol Myers Squibb), and Eli Lilly and Company. (Albany, USA) DelveInsight's ' Crohn's Disease Market Insights, Epidemiology, and Market Forecast-2034 ' report delivers an in-depth understanding of Crohn's Disease, historical and forecasted epidemiology as well as the Crohn's Disease market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan. The Crohn's Disease market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and forecasted Crohn's Disease market size from 2020 to 2034, segmented by seven major markets. The Report also covers current Crohn's Disease treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best opportunities and assesses the underlying potential of the Crohn's Disease market. Some facts of the Crohn's Disease Market Report are: The Crohn's disease market size in the 7MM was observed to be USD ~9,000 million in 2023, which is expected to increase by 2034. Key Crohn's Disease Therapies expected to launch in the market are ENTYVIO (Vedolizumab), STELARA (Ustekinumab), VELSIPITY (etrasimod), Zeposia (Ozanimod; RPC1063), LY-3074828 (mirikizumab), RHB-104, and others. In Feb 2025, Janssen Research & Development, LLC announced results of a Phase 4, Single Arm, Open-Label, 52-Week, Multicenter Study to Evaluate the Safety and Efficacy of Ustekinumab (STELARA), an Anti-Interleukin-12/23 Monoclonal Antibody, in Chinese Participants With Moderately to Severely Active Crohn's Disease In Feb 2025, Janssen Research & Development, LLC announced results of a Phase 3, Open-label, Multicenter Study to Evaluate the Safety and Efficacy of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease In Jan 2025, Eli Lilly and Company announced results of a Phase 3, Multicenter, Open-Label, Long-Term Extension Study to Evaluate the Long-Term Efficacy and Safety of Mirikizumab in Patients With Crohn's Disease On October 14, 2024, Eli Lilly and Company reported that more patients with moderately to severely active Crohn's disease treated with mirikizumab achieved histologic response at Week 52 compared to ustekinumab, regardless of prior biologic experience. The VIVID-1 study is the first Phase 3 trial to report histologic outcomes using a systematic assessment of bowel segments, following ECCO guidelines. These results are being presented at UEG Week in Vienna from October 12-15. On October 14, 2024, Johnson & Johnson reported positive results for TREMFYA (guselkumab) in Crohn's disease and ulcerative colitis at the United European Gastroenterology (UEG) Week 2024. The data showed high rates of endoscopic remission in biologic-naïve and biologic-refractory patients, including those unresponsive to JAK inhibitors. These findings from the Phase III GALAXI 2 & 3 studies and the QUASAR maintenance study suggest TREMFYA could be a valuable treatment option for patients who have not responded to other biologics. Leading Crohn's Disease companies working in the market are Takeda Pharmaceutical, Janssen Pharmaceuticals, UCB, Biogen, AbbVie, AstraZeneca, Tillotts Pharma (Zeria Pharmaceutical), Gilead Sciences and Galapagos NV, Boehringer Ingelheim, Celgene (Bristol Myers Squibb), Eli Lilly and Company, RedHill Biopharma, Arena Pharmaceuticals, Mesoblast, and others. On October 14, 2024, Dong-A-ST announced that its Imuldosa (ustekinumab-srlf/DMB-3115), a biosimilar to Stelara, received FDA approval for the treatment of autoimmune diseases such as plaque psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis. Stelara, a blockbuster drug developed by Janssen Biotech, generated $10.86 billion in sales globally in 2023, and Imuldosa's approval as a biosimilar offers a more cost-effective alternative for patients requiring long-term therapy for autoimmune conditions. Crohn's Disease Overview Crohn's Disease is a chronic inflammatory bowel disease (IBD) that causes inflammation in the gastrointestinal (GI) tract, most commonly affecting the small intestine and colon. This progressive condition leads to symptoms such as abdominal pain, persistent diarrhea, fatigue, weight loss, and malnutrition. The exact cause of Crohn's Disease remains unclear, but it is believed to result from a combination of genetic, environmental, and immune system factors. The disease presents in different forms, including ileocolitis (affecting the ileum and colon), ileitis (limited to the ileum), gastroduodenal Crohn's Disease (impacting the stomach and duodenum), jejunoileitis (small intestine inflammation), and Crohn's colitis (restricted to the colon). Complications such as strictures, fistulas, abscesses, and bowel obstructions can occur, requiring advanced medical intervention. Treatment options for Crohn's Disease aim to manage inflammation, alleviate symptoms, and prevent flare-ups. Common therapies include aminosalicylates, corticosteroids, immunomodulators, biologics (such as TNF inhibitors and integrin inhibitors), and JAK inhibitors. In severe cases, surgery may be necessary to remove damaged portions of the intestine. Ongoing research focuses on new targeted therapies, gut microbiome modulation, and personalized treatment approaches to improve long-term outcomes for Crohn's Disease patients. Learn more about Crohn's Disease treatment algorithms in different geographies, and patient journeys. Contact to receive a sample @ Crohn's Disease Prevalence Crohn's Disease Market The Crohn's disease market is a rapidly evolving segment in the healthcare industry, driven by increasing prevalence, advances in treatment options, and a growing focus on precision medicine. Crohn's disease, a chronic inflammatory bowel disease (IBD), affects the gastrointestinal tract, causing symptoms like abdominal pain, diarrhea, weight loss, and fatigue. Its progressive nature often leads to complications, necessitating long-term management. The market is dominated by biologics, including tumor necrosis factor (TNF) inhibitors such as infliximab and adalimumab, which remain the cornerstone of treatment. However, emerging therapies like interleukin inhibitors (ustekinumab) and Janus kinase (JAK) inhibitors (upadacitinib) are gaining traction due to improved efficacy and targeted mechanisms of action. Small molecule drugs and biosimilars are further expanding therapeutic options, offering cost-effective solutions. Key players in the market include AbbVie, Janssen Pharmaceuticals, Takeda, UCB, and Gilead Sciences, among others. The pipeline for Crohn's disease treatments is robust, with several novel agents focusing on enhancing efficacy, safety, and patient convenience. Regional markets such as North America and Europe lead in revenue due to advanced healthcare infrastructure and higher awareness. The market's future is shaped by increasing patient populations, innovative treatment approaches, and ongoing research into the disease's underlying mechanisms. Crohn's Disease Epidemiology The Crohn's Disease epidemiology section provides insights into the historical and current Crohn's Disease patient pool and forecasted trends for seven individual major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the Crohn's Disease market report also provides the diagnosed patient pool, trends, and assumptions. Crohn's Disease Drugs Uptake This section focuses on the uptake rate of the potential Crohn's Disease drugs recently launched in the Crohn's Disease market or expected to be launched in 2020-2034. The analysis covers the Crohn's Disease market uptake by drugs, patient uptake by therapies, and sales of each drug. Crohn's Disease Drugs Uptake helps in understanding the drugs with the most rapid uptake and the reasons behind the maximal use of new drugs and allows the comparison of the drugs based on Crohn's Disease market share and size, which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions. Crohn's Disease Pipeline Development Activities The Crohn's Disease report provides insights into different therapeutic candidates in Phase II, and Phase III stages. It also analyses Crohn's Disease key players involved in developing targeted therapeutics. Download the report to understand which factors are driving Crohn's Disease market trends @ Crohn's Disease Market Insights Crohn's Disease Therapeutics Assessment Major key companies are working proactively in the Crohn's Disease Therapeutics market to develop novel therapies which will drive the Crohn's Disease treatment markets in the upcoming years are Takeda Pharmaceutical, Janssen Pharmaceuticals, UCB, Biogen, AbbVie, AstraZeneca, Tillotts Pharma (Zeria Pharmaceutical), Gilead Sciences and Galapagos NV, Boehringer Ingelheim, Celgene (Bristol Myers Squibb), Eli Lilly and Company, RedHill Biopharma, Arena Pharmaceuticals, Mesoblast, and others. Crohn's Disease Report Key Insights 1. Crohn's Disease Patient Population 2. Crohn's Disease Market Size and Trends 3. Key Cross Competition in the Crohn's Disease Market 4. Crohn's Disease Market Dynamics (Key Drivers and Barriers) 5. Crohn's Disease Market Opportunities 6. Crohn's Disease Therapeutic Approaches 7. Crohn's Disease Pipeline Analysis 8. Crohn's Disease Current Treatment Practices/Algorithm 9. Impact of Emerging Therapies on the Crohn's Disease Market Table of Contents 1. Key Insights 2. Executive Summary 3. Crohn's Disease Competitive Intelligence Analysis 4. Crohn's Disease Market Overview at a Glance 5. Crohn's Disease Disease Background and Overview 6. Crohn's Disease Patient Journey 7. Crohn's Disease Epidemiology and Patient Population 8. Crohn's Disease Treatment Algorithm, Current Treatment, and Medical Practices 9. Crohn's Disease Unmet Needs 10. Key Endpoints of Crohn's Disease Treatment 11. Crohn's Disease Marketed Products 12. Crohn's Disease Emerging Therapies 13. Crohn's Disease Seven Major Market Analysis 14. Attribute Analysis 15. Crohn's Disease Market Outlook (7 major markets) 16. Crohn's Disease Access and Reimbursement Overview 17. KOL Views on the Crohn's Disease Market 18. Crohn's Disease Market Drivers 19. Crohn's Disease Market Barriers 20. Appendix 21. DelveInsight Capabilities 22. Disclaimer About DelveInsight DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector. · In Feb 2025, Janssen Research & Development, LLC announced results of a Phase 4, Single Arm, Open-Label, 52-Week, Multicenter Study to Evaluate the Safety and Efficacy of Ustekinumab (STELARA), an Anti-Interleukin-12/23 Monoclonal Antibody, in Chinese Participants With Moderately to Severely Active Crohn's Disease · In Feb 2025, Janssen Research & Development, LLC announced results of a Phase 3, Open-label, Multicenter Study to Evaluate the Safety and Efficacy of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease · In Jan 2025, Eli Lilly and Company announced results of a Phase 3, Multicenter, Open-Label, Long-Term Extension Study to Evaluate the Long-Term Efficacy and Safety of Mirikizumab in Patients With Crohn's Disease
Globe and Mail
31-01-2025
- Business
- Globe and Mail
c-MET NSCLC FDA Approvals, Clinical Trials Assessment, Pipeline Insights, and Companies
DelveInsight's, 'C-MET Non-Small Cell Lung Cancer (C-MET+ NSCLC) Pipeline Insight' report provides comprehensive insights about 20+ companies and 20+ pipeline drugs in C-MET Non-Small Cell Lung Cancer pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Explore the comprehensive insights by DelveInsight and stay ahead in understanding the c-MET-NSCLC Treatment Landscape. Click here to read more @ c-MET-NSCLC Pipeline Outlook Key Takeaways from the c-MET-NSCLC Pipeline Report In January 2025:- AbbVie:- A Phase 3 Open-Label, Randomized, Controlled, Global Study of Telisotuzumab Vedotin (ABBV-399) Versus Docetaxel in Subjects With Previously Treated c-Met Overexpressing, EGFR Wildtype, Locally Advanced/Metastatic Non-Squamous Non-Small Cell Lung Cancer. DelveInsight's c-MET-NSCLC pipeline report depicts a robust space with 20+ active players working to develop 20+ pipeline therapies for c-MET-NSCLC treatment. The leading c-MET-NSCLC Companies such as AbbVie, Janssen Research & Development, Beijing Pearl Biotechnology Limited Liability Company, Novartis, and others. Promising C-MET NSCLC Therapies such as Glumetinib, Tepotinib, INC280, APL-101 Oral Capsules, MCLA-129, Osimertinib, and others. Stay informed about the cutting-edge advancements in c-MET NSCLC treatments. Download for updates and be a part of the revolution in cancer care @ c-MET NSCLC Clinical Trials Assessment c-MET NSCLC Emerging Drugs Profile JNJ-61186372: Janssen Research & Development, LLC JNJ-6372 is an EGFR-MET bispecific antibody with immune cell-directing activity that targets activating and resistant EGFR and MET mutations and amplifications. The production and development of the antibody followed Janssen's licensing agreement with Genmab for use of its DuoBody technology platform. According to the company, JNJ-6372 is a novel bispecific antibody that has the potential to benefit patients with Exon 20 mutation insertions who often do not respond to currently available oral EGFR-targeted or immune checkpoint inhibitor therapies. PLB1001 - Beijing Pearl Biotechnology Limited Liability Company PLB1001 is an orally bioavailable inhibitor of the proto-oncogene c-Met (hepatocyte growth factor receptor; HGFR) with potential antineoplastic activity. Upon administration, PLB1001 selectively binds to c-Met, thereby inhibiting c-Met phosphorylation and disrupting c-Met signal transduction pathways. This may induce cell death in tumor cells overexpressing c-Met protein or expressing constitutively activated c-Met protein. c-Met, a receptor tyrosine kinase overexpressed or mutated in many tumor cell types, plays key roles in tumor cell proliferation, survival, invasion, metastasis, and tumor angiogenesis. c-MET NSCLC Companies AbbVie, Janssen Research & Development, Beijing Pearl Biotechnology Limited Liability Company, Novartis, and others. C-MET Non-Small Cell Lung Cancer (C-MET+ NSCLC) pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as Oral Intramuscular Intratumoral Intravenous Molecule Type c-MET NSCLC Products have been categorized under various Molecule types such as Gene therapies Bispecific antibodies Immunotherapies Monoclonal antibodies Small molecules Product Type Discover the latest advancements in c-MET NSCLC treatment by visiting our website. Stay informed about how we're transforming the future of oncology @ c-MET NSCLC Market Drivers and Barriers, and Future Perspectives Scope of the c-MET NSCLC Pipeline Report Coverage- Global c-MET NSCLC Companies- AbbVie, Janssen Research & Development, Beijing Pearl Biotechnology Limited Liability Company, Novartis, and others. C-MET NSCLC Therapies- Glumetinib, Tepotinib, INC280, APL-101 Oral Capsules, MCLA-129, Osimertinib, and others. c-MET NSCLC Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination c-MET NSCLC Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III For a detailed overview of our latest research findings and future plans, read the full details of c-MET NSCLC Pipeline on our website @ c-MET NSCLC Emerging Drugs and Companies Table of Content Introduction Executive Summary C-MET Non-Small Cell Lung Cancer (C-MET+ NSCLC): Overview Pipeline Therapeutics Therapeutic Assessment C-MET Non-Small Cell Lung Cancer (C-MET+ NSCLC) – DelveInsight's Analytical Perspective In-depth Commercial Assessment C-MET Non-Small Cell Lung Cancer (C-MET+ NSCLC) Collaboration Deals Mid Stage Products (Phase II) Telisotuzumab: AbbVie PLB1001: Beijing Pearl Biotechnology Limited Liability Company Drug profiles in the detailed report….. Early Stage Products (Phase I) JNJ-61186372: Janssen Research & Development, LLC Drug profiles in the detailed report….. Pre-clinical and Discovery Stage Products Drug profiles in the detailed report….. Inactive Products C-MET Non-Small Cell Lung Cancer (C-MET+ NSCLC) Key Companies C-MET Non-Small Cell Lung Cancer (C-MET+ NSCLC) Key Products C-MET Non-Small Cell Lung Cancer (C-MET+ NSCLC)- Unmet Needs C-MET Non-Small Cell Lung Cancer (C-MET+ NSCLC)- Market Drivers and Barriers C-MET Non-Small Cell Lung Cancer (C-MET+ NSCLC)- Future Perspectives and Conclusion C-MET Non-Small Cell Lung Cancer (C-MET+ NSCLC) Analyst Views C-MET Non-Small Cell Lung Cancer (C-MET+ NSCLC) Key Companies Appendix About Us DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve. Media Contact Company Name: DelveInsight Business Research LLP Contact Person: Yash Bhardwaj Email: Send Email Phone: 9650213330 Address: 304 S. Jones Blvd #2432 City: Las Vegas State: Nevada Country: United States Website:
